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Abstract
Acute and chronic pain control is a significant clinical challenge that has been largely unmet.
Local anesthetics are widely used for the control of post-operative pain and in the therapy of acute
and chronic pain. While a variety of approaches are currently used to prolong the duration of
action of local anesthetics, an optimal strategy to achieve neural blockage for several hours to days
with minimal toxicity has yet to be identified. Several drug delivery systems such as liposomes,
microparticles and nanoparticles have been investigated as local anesthetic delivery vehicles to
achieve prolonged anesthesia. Recently, injectable responsive hydrogels raise significant interest
for the localized delivery of anesthetic molecules. This paper discusses the potential of injectable
hydrogels to prolong the action of local anesthetics.

Author Manuscript

Pain is the most common presenting complaint to physicians as a result of accidental or
sports related injuries and various diseases. A number of factors influence an individual’s
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reaction to pain including age, cultural background, perception, past experiences, social
expectations, physical and mental health, parental attitudes concerning pain, fear, anxiety,
fatigue and the setting in which pain occurs [1,2]. The experience of pain can be broadly
classified into acute and chronic pain [3]. Acute pain can be modulated and removed by
treating its cause and is usually a sequel to surgery or trauma. Chronic pain is more complex
and the source of pain may be difficult to eliminate. Relieving pain has been shown to result
in improved healing, faster recovery and an earlier return to former activities and lifestyle
[4].

Author Manuscript
Author Manuscript

The two major classes of analgesics used for treating pain are opioids and nonsteroidal antiinflammatory drugs (NSAIDs). The primary mode of action of these analgesics differs;
some act centrally, some peripherally and others exert their effect at multiple locations.
First-line treatments for pain usually involve nonopioid analgesic agents including aspirin,
paracetamol and NSAIDs. These nonopioid analgesics have advantageous in relieving acute
pain because they are readily available without a prescription, relatively inexpensive and
easy to use. However, many of these nonopioid drugs may only be effective for mild to
moderate pain. For patients with moderate to severe pain, opioid analgesics or nonopioid
analgesics combined with other analgesic agents are considered. Opioids such as morphine
are considered as the gold standard for the management of pain [5]. However, opioid
treatments are often associated with a wide range of side effects such as splinting, sedation,
nausea, vomiting, impaired bowel motility and development of tolerance (particularly in the
case of chronic pain management) [6]. Even though opioids are known to produce analgesia
primarily through their actions in the central nervous system, studies have shown the
presence and activation of peripheral opioid receptors in painful inflammatory conditions
[7]. These drugs provide a critical armamentarium of pain management options and
continued research toward development of more potent, more site specific, less toxic and
less abusable molecules will further enhance their utility.

Author Manuscript

The use of local anesthetics to treat pain has many potential advantages compared with the
systemic administration of opioid analgesics, in situations where the cause and source of the
pain is limited to a particular site or region [8]. It is often used as an adjunct to systemic
analgesia, or to provide epidural or anesthesia. Offsetting the use of opioids and NSAIDS
with local blockade permits the use of smaller amounts of systemic drugs, thus lowering
risks of side effects and potential toxicity. Natural-derived and synthetic local anesthetic
molecules, specifically amino amides and amino esters, are currently under investigation
(Table 1) [9]. Common local anesthetics include bupivicaine, chloroprocaine, lidocaine,
procaine and tetracaine. They work by numbing the target area without causing
unconsciousness. The underlying molecular mechanism of local anesthetics is mainly the
inhibition of sodium influx through voltage-gated sodium-specific ion channels in the
neuronal cell membrane, which prevents transmission of nerve impulses where local
anesthetics are applied [10]. Recent research efforts have been focused on establishing
appropriate formulations in order to optimize therapeutic efficacy [11]. For instance, eutectic
mixture of local anesthetics, known as EMLA, is a mixture of equal amounts of two wellknown local anesthetics, prilocaine and lidocaine. EMLA is designed for topical anesthesia
during blood sampling, placement of intravenous cannulae and minor superficial procedures
[12,13]. Similarly, a eutectic mixture of lidocaine and tetracaine is used to numb the skin
Ther Deliv. Author manuscript; available in PMC 2015 December 01.
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before certain minor procedures [12] and tetracaine-epinephrine-cocaine (TAC) solution is
indicated as a local dermal anesthetic for the emergency treatment of uncomplicated
lacerations [14]. While promising, utilizing synthetic local anesthetic formulations has the
potential to cause significant health issues, such as systemic toxicity and adverse local tissue
reaction [9,11,15,16].

Author Manuscript

Current research, therefore, has been focused on the identification of novel local anesthetics
with protracted analgesic effect and minimal toxicity. Pharmacological studies have revealed
the potent analgesic activity of several neurotoxins isolated from animals, plants and marine
organisms. These naturally derived molecules are of particular interest because of their
strong pharmacological activity, selectivity, low cytotoxicity and specificity for the site of
action. For instance, α-cobratoxin (α-CTx), isolated from the Thailand Cobra, has strong
affinity for the α7 subunit of the nAChR (α7nAChR) neuronal receptor [17], which is
predominantly located in the peripheral nervous system. It is believed that activation of
α7nAChR by αCTx leads to the depolarization of postsynaptic membranes and the
prevention of neurotransmitter release [18]. Thus, αCTx has significant potential to serve as
a new regimen to combat localized pain with long-lasting analgesic activity, nondependence,
relatively low cost and commercial availability [19]. More well-controlled clinical studies
are needed to establish the benefits of utilizing naturally derived local anesthetics on
patients. In addition, future research will be able to identify additional analgesic molecules
for localized pain relief that are more affordable, safer and have longer lasting effects
compared with the presently available medications.

Author Manuscript

Several biomaterial based controlled delivery systems are currently been investigated as an
alternative approach to extend the activity of fast-acting local anesthetic molecules.
Controlled delivery local anesthetic formulations have the potential to serve as a safe,
localized, long-acting postoperative pain management system. Several carriers including
liposomes, microparticles and nanoparticles have been investigated with some success;
however, they can freely diffuse from the injection site presenting limitations for long-term
localized anesthesia. Recently, research has been focused on developing responsive
hydrogel carriers as unique delivery vehicles for local anesthetic molecules. The review
focuses on the recent advances in the area of hydrogel based carriers for prolonged delivery
of local anesthetic molecules.

Long-acting local anesthetics for orthopedic applications

Author Manuscript

The usage of long-acting local anesthetics in the management of chronic pain in
orthopaedics is twofold: to enable diagnosis of some chronic pain conditions and to provide
relief for some nonsurgical pain conditions [20,21]. Table 2 shows some chronic pain
diagnoses in which local anesthetics play a role in treatment and management:
Clinically, local anesthetics cause a reversible loss of nociception and local anesthesia. In
the treatment of chronic pain, local anesthetics can be applied to a number of tissues,
including nerve, joint and muscle. When used on nerve structures (nerve block), specific
local anesthetic effects include analgesia (loss of pain sensation) and paralysis (loss of
muscle power). A delicate balance between these two effects, analgesia and paralysis, must
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be obtained to optimally treat patients clinically. For the treatment of chronic pain, which is
typically an outpatient service, analgesia rather than paralysis is the desired effect by a
number order of magnitude. Simply put, the clinician wants the patient to have reduced pain
but to be able to walk out of the office and go back home. Thus, a local anesthetic with a
longer duration of action and a potency that gives a sensory block with minor motor block
would be very valuable for the practicing clinician.

Author Manuscript

Spinal facet joint mediated pain is diagnosed with either an intra-articular joint injection or a
medial branch nerve block. A longer acting injectable local anesthetic, one that lasts 7–20
days, can give the patient longer pain relief so as to complete a course of physical therapy or
lend to specific diagnosis. This may also be true with the diagnosis of SI joint mediated
pain, which is diagnosed similarly to facet joint mediated pain. In myofacial pain
syndromes, such as trigger points and fibromyalgia, physical therapy is the mainstay of
treatment. Local anesthetic injections are used to cause analgesia in the painful muscles
while a patient completes physical therapy. The longer acting the medication is (e.g., 7–20
days), the fewer injections the patient will need during an 8 to 12 week course of physical
therapy. A longer acting local anesthetic can also assist with long-term treatment and
diagnosis of sympathetically mediated pain syndromes such as complex regional pain
syndromes of the extremities. Lastly, localized peripheral neuropathies, such as meralgia
paresthetica and occipital neuralgia, are typically treated with long-acting local anesthetics.

Author Manuscript

Clinically the duration of action, toxicities and patient-specific factors (such as allergies)
largely determine the choice of anesthetics used. The currently used depo-long acting
versions of the injectable local anesthetics provide prolonged anesthesia due to the inherent
structure of the anesthetic rather than from the delivery mechanism. Examples include
lidocaine (moderate potency and duration), procaine (low potency and duration) and
bupivacaine (high potency and duration). Increasing the drug concentration (e.g., 1%
lidocaine vs 2% lidocaine), can increase the duration but can also increase the medication’s
potency this in turn can increase the risk of toxicity and motor nerve involvement (loss of
muscle power) [22]. Transdermal lidocaine, via either ointment or patch, has a long duration
of action but also has some negative factors. The disadvantages are the low depth of skin
penetration limits medication usage to topical surface structures such as the knee joint, and
the gel or patch occasionally does not fit the treated location nor stay in place.

Author Manuscript

Systemic anesthetic usage has very few indications in the treatment of chronic pain. One
such group of pain diagnoses is chronic neuropathic pain. Broader indications for their use
are with cardiac arrhythmic care. However, the window between toxicity and clinically
useful dosing for systemic anesthetics is very narrow. Local anesthetics are safer than
general or systemic anesthetics; therefore, they are used whenever possible. In addition,
local anesthetics are relatively easy to administer and readily available. However, high doses
of local anesthetics also have significant side effects as discussed before. One such
anesthetic with some limitations due to toxicity is bupivacaine and its application in joint
injections [23]. This has not been determined for muscle or nerve tissues and as such
bupivacaine is used for diagnosis and treatment for some painful conditions associated with
these tissues. Bupivacaine is long acting so it does have value, but a long acting 1 or 2%
lidocaine could be used in its place when toxicities or allergies are a concern.

Ther Deliv. Author manuscript; available in PMC 2015 December 01.
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In summary, the use of long-acting local anesthetics that elicit complete neural blockage for
several hours to days is highly desirable in the management of acute and chronic pain [24].
Current research is focused on developing controlled release strategies to prolong the action
of the existing anesthetic molecules over a period of days rather than hours, with reduced
side effects, to significantly enhance their utility in pain management.

Responsive hydrogels

Author Manuscript

It has been widely acknowledged that responsive hydrogels may have potential in the
biomedical and pharmaceutical fields as a minimally invasive delivery system with
controlled release properties [25–27]. Hydrogels are cross-linked networks of hydrophilic
polymers with very high water content [28]. The tissue-mimic properties of hydrogel
matrices have been shown to be effective in the controlled release of drugs as well as
scaffolds for tissue engineering.
Recently, research has focused on developing ‘smart’ or ‘intelligent’ hydrogels that have the
ability to respond to subtle changes in the surrounding environment [29–32]. The potential
of ‘smart’ hydrogels stems from their ability to make rapid structural changes, volume-phase
transitions or sol-gel transitions in response to certain stimuli [29,30,33]. Reactions may be
triggered by a number of environmental changes, with the most extensively studied being
thermo-responsive and pH-sensitive hydrogels [34]. Hydrogels have also been developed to
respond to other external triggers such as light, ions, protein, DNA and electromagnetic
radiation [28–34]. Recently, hydrogels have been developed that can respond
simultaneously to multiple triggers, such as pH and temperature [35].
Thermo-sensitive hydrogels

Author Manuscript

Thermo-sensitive hydrogels are among the most heavily investigated type of stimuliresponsive hydrogels due to their practical applications in vitro and in vivo [36–38].
Polymers with critical solution temperatures are of interest in drug delivery, particularly
those with a lower critical solution temperature (LCST) at or near physiological temperature.
These polymers near LCST exhibit a decrease in solubility resulting in sol-gel transition,
and an LCST near 37°C allowing them to be injected and undergo gelation within the body.

Author Manuscript

One of the most widely studied LCST polymers is poly(N-isopropylacrylamide),
(PNIPAAM) [39,40]. PNIPAAM is a synthetic water soluble polymer with an LCST of
around 32°C in distilled water [41–43]. Studies have demonstrated the feasibility to
modulate the chemistry of the polymer to adjust the LCST closer to the body temperature of
37°C. The addition of hydrophilic co-monomers has been shown to increase the LCST of
PNIPAAM whereas the addition of hydrophobic comonomers has been shown to decrease
the LCST [44,45]. In spite of its unique properties, PNIPAAM has a number of limitations
such as nondegradability and potential toxicity to serve as a suitable candidate for drug
delivery [46].
Poly(ethylene glycol) (PEG) is another synthetic polymer extensively investigated to
develop thermoresponsive hydrogels [47–51]. PEG is an ideal candidate to serve as the
hydrophilic block in these hydrogel systems due to its biocompatibility, FDA approval status
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and its availability in a variety of telechelic end groups. One of the most commonly
investigated thermoresponsive PEG-based injectable hydrogel is poly(ethylene oxide)poly(propylene oxide)-poly(ethylene oxide) copolymers (Pluronic) [52]. However, the
nondegradability and poor in vivo stability of the Pluronics are considered limitations for
clinical applications [53]. Recent effort has therefore, been focused on developing
biodegradable PEG-based injectable hydrogels with degradable hydrophobic blocks such as
poly(ε-caprolactone), polyesters and polyurethanes [54–56].
Intra-molecular hydrogen bonding and hydrophobic interactions in natural biodegradable
and biocompatible polymers, such as chitosan, have also been extensively investigated to
develop thermo-sensitive polymers. For instance, acidic chitosan solutions, when neutralized
at low temperature using β-glycerophosphate or ammonium hydrogen phosphate, remain in
solution at room temperature and can undergo gelation at or near 37°C [57,58].

Author Manuscript

Photo responsive hydrogels
In photo responsive hydrogels, light serves as the stimuli to induce a sol-gel phase transition.
Both ultraviolet (UV) and visible light have been extensively investigated. Photo responsive
hydrogels that are stimulated by visible light provide advantages over UV induced hydrogels
since they are readily available, safe and cost effective [29,46].

Author Manuscript

Visible light responsive hydrogels have been developed as a potential biomaterial with
stimuli sensitive properties [59]. PNIPAAM hydrogels modified with chromophore, such as
trisodium salt of copper chlorophyllin, have been shown to undergo differential swelling
when irradiated with visible light. In the presence of visible light, the chromophore releases
heat, thereby increasing the temperature of the polymer network. Since PNIPAAM hydrogel
is thermo sensitive as discussed earlier, the increase in temperature impacts the swelling of
the hydrogel and thereby affecting drug diffusion.
In addition to photo-responsive hydrogels, photo-cross-linked hydrogels are raising
significant attention as drug delivery vehicles. Biodegradable, photo-curable polymers form
a versatile class of injectable biomaterials as the aqueous polymer solution can be injected
followed by photo-curing in situ using fiber optic cables. Several photo-curable
biodegradable gel systems have been developed [60]. One of the limitations of photo-crosslinkable systems is the light attenuation by the initiators, restricting the maximum attainable
cure depth to only a few millimeters [61]. To circumvent the limitations of photo
polymerized systems, several chemically cross-linked polymeric systems have been
developed using functionalized polymers with reactive groups such as thiols, phenols and
aldehydes [62–66].

Author Manuscript

pH-sensitive hydrogels
Changes in pH occur at a number of sites within the body including the stomach, intestine,
lysosome, endosome and extracellular tumor sites [67–69]. These pH variations could
therefore be used to trigger a site specific drug release from a pH responsive hydrogel. All
pH-responsive hydrogels contain an ionizable acidic or alkaline group, which is able to
respond to variations in pH or target specific tissue based on physiological pH [69]. When
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ionized, these functional groups create a repulsion that results in the swelling of the
hydrogel. The extent of the swelling of the hydrogel is determined by the degree to which
the functional group in the polymer can be ionized [67]. Swelling will occur at the pKa of
the functional group and has been found effective with groups with pKa’s ranging from 3 to
10 [69]. Functional groups often found in pH sensitive hydrogels are weak acids or bases
such as carboxylic acid, phosphoric acid, sulfonic acid and amines [30]. The most frequently
studied pH responsive hydrogels are poly(acrylic acid) [70], poly(methacrylic acid) [71],
poly(ethylene imine) [72], chitosan [73], poly(L–lysine) [74] and poly(L–histidine) due to
the presence of carboxylic or amino groups in these polymers [75]. One of the limitations
inherent in synthetic pH-sensitive hydrogels is that they are not biodegradable and therefore
must be removed, thereby limiting their in vivo applications [46].

Hydrogels as localized anesthetic delivery systems
Author Manuscript

As discussed before, prolonged duration of local anesthetics is a significant current clinical
need. Hydrogel systems have been extensively investigated for the sustained localized
delivery of small molecules and macromolecules for various indications. These include
growth factor delivery for tissue engineering, anti-cancer agents for localized chemotherapy
and insulin delivery for diabetes [76]. Recently, significant interest has gone toward
developing hydrogels as local anesthetic delivery vehicles due to the minimally invasive
application possible with many injectable hydrogel systems, and the ability to localize the
drug at the intended site [11] (Table 3).

Author Manuscript
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Seol et al. developed a Pluronic F127/hyaluronic acid (HA) based gel with thermosensitive
properties, which gels quickly upon exposure to body temperature, as a sustained delivery
vehicle for a nonopioid local anesthetic, bupivacaine hydrochloride (BH) [77]. The authors
demonstrated the feasibility of injecting and localizing the gel in situ, as well as the
sustained release of the drug from the gel over a period of several days in vitro. The BH
released from the gel was found to be less cytotoxic to L929 fibroblastic cells compared
with adding BH directly to the culture media, presumably due to the slow release of BH
from the gel. Similarly, Bernardo et al., developed a dual pH- and thermo-sensitive hydrogel
system for the sustained delivery of bupivacaine [78]. The polymeric system used included
copolymers of poly(acrylamide-co-monomethyl itaconate; A/MMI) cross-linked with N,N′methylene bisacrylamide (NBA). The swelling behavior of the hydrogel depended on the pH
of the medium. Also during the initial stages both swelling and drug release kinetics were in
accordance with the second Fick’s law. The system showed the feasibility to modulate the
release profile of bupivacaine by changing the pH; a 60% release was observed at pH 7.5,
whereas approximately 80% release was observed at pH 1.5. These pH sensitive hydrogels
have the potential to serve as efficient delivery system to deliver analgesics to organs such
as stomach that involves significant changes in pH.
As indicated before, long-lasting anesthetic is helpful during the post-operative period. Yin
et al., investigated a composite hydrogel-nanoparticle system for the extended release of
hydrophobic drugs, such as lidocaine [79]. Lidocaine was loaded into biodegradable PCLPEG-PCL (PCEC) nanoparticles, and the nanoparticles were then suspended in a
thermogelling Pluronic solution. The thermogelling solution can be injected into the body,
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where it gels upon exposure to the physiological temperature thereby localizing the
nanoparticles to the point of application. A sustained drug release profile was observed due
to the diffusion of the drug from the nanoparticles. The in vivo efficacy of the system was
evaluated in subcutaneous rat model and measured by tail flick latency tests. The Lidocanenanogel produced effective anesthesia for 360 ± 13 min compared with lidocaine delivered
directly from the gel (150 ± 33 min) and lidocaine solution (110 ± 45 min). Nano and
microparticles have been previously explored as drug delivery vehicles for local anesthetics.
The study demonstrated the potential of further improving the efficacy and localization of
these carriers by combining them with hydrogel systems.

Author Manuscript

Similarly, Chen et al., developed an injectable microparticle-gel system for prolonged and
localized release of lidocaine [80]. In this study, lidocaine-loaded degradable poly(lactic-coglycolic acid) microparticles were suspended in thermosensitive poloxamer 407 solution.
The in vivo efficacy of the system was evaluated using a rat sciatic nerve blockade model by
monitoring the sensory and motor functions. The study demonstrated that microspherepoloxamer formulation yielded the longest duration of sensory and motor block for a period
of approximately 8.5 h compared with 5 h in the case of microspheres in saline, 5 h in the
case of lidocaine in gel and 2 h by lidocaine in saline. The study corroborated the potential
of multifaceted hydrogel system in developing long-lasting local analgesic formulations.
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In another study, Jimenez-Kairuz et al., developed a sustained delivery lidoaine system
using a carbomer (polyacrylic acid) based hydrogel [81]. The carbomerlidocaine system
served as a reservoir of lidocaine wherein a high proportion of the drug existed in the form
of R-COO-LH+. An in vitro release study demonstrated that the dissociation of ion pairs
controlled the release rate of lidocaine. Moreover, the release rate can be increased by the
addition of a second counter-ion or through the diffusion of neutral salts such as sodium
chloride into the gel matrix. The study demonstrated that better understanding of the ion
paring affinity between charged drug molecules and polyelectrolyte carriers would help to
predict the release kinetics under different conditions. Loughlin et al., studied the role of
polyol sugars in modulating the properties of tetra-hydroxyborate cross-linked poly(vinyl
alcohol) gels as lidocaine delivery system [82]. Addition of the hydrochloride salt of
lidocaine can lead to network constriction of poly(vinyl alcohol) induced by ionic and pH
effects making it unsuitable for topical applications. The study demonstrated that the
addition of D-mannitol can circumvent the problem. A formulation with 2% mannitol
showed an initial burst release of lidocaine and a drug release mechanism dependent on
temperature with a diffusion controlled release profile.

Author Manuscript

In addition to nanospheres, thermo-responsive nanogel systems have also been developed to
achieve prolonged duration of local anesthesia [83]. The thermo-responsive nanogels were
developed from PNIPAAM and their tunable size, number of functional groups, thermoresponsiveness and anionic charge make them attractive candidates for prolonged drug
release. In vivo studies using a rat sciatic nerve blockade model demonstrated nerve block
durations of up to 9 h using acrylic acid conjugated nanogels loaded with bupivacaine. The
study also demonstrated the feasibility to modulate the release by changing the composition
and size of the nanogels. Increasing the anionic charge density of the nanogels and
decreasing the nanogel size facilitated longer duration of anesthetic release.
Ther Deliv. Author manuscript; available in PMC 2015 December 01.
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Apart from these nondegradable polymer systems, several injectable and degradable
hydrogel systems have been developed for local anesthetic delivery. Jia et al., investigated
the feasibility of using hydrazide and aldehyde modified HA as an injectable delivery
vehicle for bupivacaine [84]. The efficacy of the system was evaluated in a rat sciatic nerve
blockade model. It was reported that a 2% cross-linked HA doubled the duration of block of
0.1–0.5% bupivacaine, without a statistically significant increase in myotoxicity. The 1%
cross-linked HA also prolonged the nerve block compared with uncross-linked HA
demonstrating the role of polymer cross-linking in prolonging the effect of local anesthetics.
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Hoare et al., recently developed rheological polymer blends of HA and
hydroxypropylmethyl cellulose (HPMC) as another approach to achieve sustained delivery
of local anesthetics [85]. In a rat sciatic nerve blockade model, HA-HPMC loaded with
bupivacaine prolonged the sensory block approximately threefold compared with
bupivacaine solution. Incorporation of HPMC modulated the rheological property of the
formulation, thereby allowing better polymer injection and reduced polymer hydration,
leading to sustained drug release. Moreover, the blends exhibited no cytotoxicity in vivo
with a mild short-term inflammatory reaction at the site of injection and were largely
resorbed by four days post injection.
Pignatello et al., investigated the potential of chitosan glutamate hydrogels as localized
anesthetic delivery vehicles for buccal application [86]. Chitosan hydrogels are known to
prolong both the retention times on the oral mucosa as well as drug release. The anesthetic
activity of mucoadhesive lidocaine-loaded chitosan gels was accessed in healthy volunteers
and demonstrated its potential to reduce pain symptoms that characterize aphthosis and other
mouth diseases.
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We have investigated the feasibility of using thermogelling chitosan formulation as an
injectable localized and sustained delivery vehicle for ropivacaine [11]. Ropivacaine (N-npropyl 2′,6′-pipecoloxylidide) is an amino-amide local anesthetic and is the propyl analogue
of bupivacaine [87]. Numerous preclinical and clinical studies have demonstrated lower
cardio- and neurotoxicity associated with ropivacaine compared with bupivacaine [88].
Ropivacaine is a pure S(-) enantiomer, while bupivacaine is a racemic mixture. Studies have
shown that enantiomerically pure drugs are less toxic when compared with racemates [89].
The lipid solubility of ropivacaine is lower than bupivacaine, which should increase tissue
retention. Ropivacaine also shows less vasodilation compared with bupivacaine and is
capable of producing mild vasoconstriction, thus further reducing the extent of systemic
plasma absorption. Another significant advantage of ropivacaine is its greater degree of
separation between sensory and motor blockade resulting in less motor block compared with
bupivacaine [90]. These attributes make ropivacaine an ideal molecule for localized
anesthesia. The chitosan thermogels were prepared by neutralizing acidic chitosan solution
with ammonium hydrogen phosphate at low temperature. At higher temperatures
(approximately 37°C), the thermogelation of the neutral solution is promoted by the
combined effect of electrostatic attraction and increased hydrophobic interactions between
polymer chains. We have demonstrated that the use of ropivacaine nanoparticles with lower
solubility, a drug action enhancer (dexamethasone) and a thermogel matrix together could
lead to a multifaceted delivery system capable of providing moderate term pain management
Ther Deliv. Author manuscript; available in PMC 2015 December 01.
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[11]. Ropivacaine-based nanoparticles were prepared as described [91]. The controlled in
vitro release of ropivacaine from the chitosan thermogel resulted in less than 50% of the
drug being released after 7 days (Figure 1). Sensory blockade for animals given two doses of
ropivacaine (75 and 150 mg/kg) along with dexamethasone in thermogel was found to be
similar to animals given ropivacaine alone (5 and 150 mg/kg doses) in thermogel at 6 h;
however, the blockade persisted much longer with slow return of sensory function over 24–
48 h in the case of (ropivacaine + dexamethasone) in the thermogel group (Figure 2). Thus,
the delivery system demonstrated efficacy for more than 30 h in vivo, providing significant
potential for clinical applications. Future studies will be focused on modulating the
degradation kinetics of the injectable formulation to further control the drug release as well
as the complete removal of the biomaterial after the intended application.
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In spite of the unique properties of photoresponsive/cross-linked hydrogel delivery systems,
they have not been extensively investigated for prolonged local anesthetic delivery.
Literature search showed only one study evaluating the potential of a photocross-linked
semi-interpenetrating network composed of poly(ethylene glycol) and gelatin to deliver
bupivacaine and silver sulfadiazine for treating wound in a swine model [92]. The study
demonstrated the feasibility to deliver these drugs from the hydrogel wound dressing and
concluded that further optimization is required to determine the drug and carrier
effectiveness.

Future perspective

Author Manuscript

Extended duration local anesthetic formulations are highly desirable for clinical use. The
development of effective delivery systems capable of modulating the release rate of local
anesthetic molecules and which enhances their localization could significantly increase the
prolonged duration of activity and reduce systemic toxicity. Recent studies demonstrated the
significant advantages in using injectable hydrogel systems for the localized prolonged
delivery of local anesthetics. In spite of its unique properties, the current hydrogel systems
can prolong the effectiveness of the drug only for few hours. The ultimate goal will be to
achieve prolonged anesthesia for 7–30 days without cytotoxicity. Combination therapy
involving local anesthetics/vasoconstrictors/NSAIDs along with injectable multifaceted
delivery systems may in the near future provide the clinicians with a broader spectrum of
formulations with varying degree of prolongation of anesthesia.

Key terms
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Local anesthetics

Anesthetics which cause loss of sensation only to the area to which
it is applied

Controlled delivery

Method to release drug over a period of time in a controlled
manner

Bupivacaine

An aminoamide local anesthetic drug

Hydrogels

Cross-linked polymer network containing aqueous solution

Lidocaine

A common local anesthetic drug
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Ropivacaine

A long-acting local anesthetic structurally related to Bupivacaine

Thermogels

Temperature sensitive hydrogels
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Executive summary
Introduction
•

Reducing the acute and chronic pain commonly associated with injuries and
diseases using analgesics has been shown to improve healing and is, therefore, a
topic of great interest.

•

Local application of analgesics has potential advantages compared to systemic
administration, including the use of smaller dosages to reduce side effects and
potential toxicity.

•

Biomaterial-based controlled delivery systems have the potential to extend the
activity of fast-acting local analgesics, in order to develop a safe, localized,
long-acting pain management system.

Author Manuscript

Long acting local anesthetics for orthopaedic applications
•

A long-lasting local anesthetic (relief for 7–20 days) is desirable for the
treatment of chronic local pain.

•

Current research is focused on developing controlled local release strategies to
maintain an optimal therapeutic level of anesthetic over a period of days, to
produce effective analgesia localized to the site of interest, and to restrict
negative side effects.

Responsive hydrogels

Author Manuscript
Author Manuscript

•

Hydrogels (cross-linked networks of hydrophilic polymers with high water
content) have potential as local, minimally invasive, controlled release delivery
systems due to their structure.

•

Responsive hydrogels are those able to change properties in response to
environmental stimuli such as temperature or pH.

•

Thermo-sensitive hydrogels transition from a liquid to gel state as the
temperature increases over a critical solution temperature specific to the
polymer.

•

Hydrogels can be modified to be light-sensitive or photo-crosslinked to allow
for stimulation of gelation via exposure to visible/UV light or photo-curing,
respectively.

•

pH-responsive hydrogels contain ionizable functional groups that can respond to
physiological variations in pH, promoting swelling of the hydrogel correlating
to the degree of ionization.

•

Responsiveness can be altered by altering the chemical structure of the
polymers, potentially allowing engineered polymers to achieve a specific
response desired for a given application.

Hydrogels as localized anesthetic delivery systems
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•

The ability to localize drug delivery through minimally invasive administrations
of hydrogels makes injectable hydrogel systems promising candidates for
sustained, localized anesthetic delivery.

•

A variety of responsive hydrogel systems for administration of bupivacaine,
ropivacaine, and lidocaine have been investigated through in vitro and in vivo
models, and have shown indications of controlled release, prolonged analgesic
effects, and low cytotoxicity.

Future perspective

Author Manuscript

•

There exists the potential for acute and chronic pain control using injectable
hydrogel systems with a localized prolonged delivery of anesthetics, without
systemic toxicity.

•

The goal of current research is to modify the hydrogel systems in order to
achieve a longer duration of anesthesia (7–30 days) without cytotoxicity.

•

Composite hydrogel-nano/microparticle systems may continue to be studied in
order to enhance efficacy, drug release kinetics, and localization capabilities of
hydrogel therapies during post-operative periods.

•

Future research may also explore novel therapies that combine local anesthetics,
vasoconstrictors, NSAIDs, and injectable multi-faceted delivery systems to
provide clinicians with a variety of approaches to prolong anesthesia for the
duration needed.
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Figure 1. Ropivacaine base released from chitosan thermogel as determined by highperformance liquid chromatography

The thermogel mediated a gradual release of the drug nanoparticles over the course of 7
days. Data are presented as mean ± standard deviation (N = 3).
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Figure 2. In vivo efficacy of the delivery system

(A) Thermal paw withdrawal latency difference and (B) composite motor function score for
animals rats given different anesthetic regimens (N ≥ 3). Chitosan thermogel delivery of
ropivacaine base nanoparticles (C + RB-75 and C + RB-150) enhanced both in vivo sensory
and motor blockade over the clinically utilized treatment (RHCl). Sensory blockade was
extended and motor blockade was enhanced by the addition of dexamethasone to the
localized anesthetic delivery system (C + RB-75 + D and C + RB-150 + D). p < 0.05 over
RHCl (#) and C + D (+). Data are presented as mean ± standard error (N ≥ 3).
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Classification of nonopioid local anesthetics.
Amino amides

Amino esters

Naturally derived local anesthetics

Articaine

Amethocaine

Cabratoxin

Bupivacaine

Benzocaine

Tetrodotoxin

Dibucaine

Chloroprocaine

Menthol

Etidocaine

Cocaine

Neosaxitoxin

Levobupivacaine

Cyclomethycaine

Saxitoxin

Lignocaine

Dimethocaine

Mepivacaine

Lidocaine

Prilocaine

Piperocaine

Ropivacaine

Propoxycaine
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Procaine
Proparacaine
Tetracaine
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Local anesthetics in treatment and diagnoses.
Local anesthetics assist with the diagnosis (and treatment) of:

Local anesthetics assist with the relief of nonsurgical chronic pain in:

Facet joint mediated pain (Medial Branch Blocks)

Sympathetically-mediated pain syndrome such as Complex Regional Pain
Syndromes (CRPS)

Sacroiliac (SI) joint mediated pain

Meralgia paresthetica

Localized myofacial pain syndromes- myofacial trigger points,
piriformis syndrome

Occipital neuralgia

Diffuse myofacial pain syndrome- fibromyalgia tender points

Post-herpetic neuralgia
Scar pain - post-epesiotomy, post-hernia repair, post- surgery
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Hydrogels for prolonged local anesthetic delivery.
Name

Type

Ref.

Pluronics F127/hyaluronic acid

Thermogel

[77]

Poly(acrylamide-co-monomethyl itaconate)

pH and thermosensitive gel

[78]

PCL-PEG-PCL nanoparticles in Pluronics

Thermogel

[79]

Poly(Lactic-co-glycolic acid) microparticles in Poloxamer 407

Thermogel

[80]

Poly(acrylic acid)

Polyelectrolyte complex

[81]

Poly(N-isopropyl acrylamide)

Thermoresponsive nanogels

[83]

Hyaluronic acid

Chemical crosslinking

[84]

Hyaluronic acid and hydroxypropylmethyl cellulose

Rheological blend

[85]

Chitosan-ammonium hydrogen phosphate

Thermogel

[11]
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